A laboratory manufacturing Pfizer’s Paxlovid in Freiburg, Germany. Fosun Pharma is also eligible to produce and supply the raw ingredients for the drug, which is called nirmatrelvir. Photo: AFP
China’s Fosun posts 26 per cent jump in net profit, gets ready to make generic Pfizer and Merck Covid-19 pills
- Pfizer licence to ‘hone Fosun Pharma’s image as a leading player’, after endorsement by UN-backed Medicines Patent Pool, analyst says
- Parent firm Fosun International reports 26 per cent year-on-year increase in net profit to US$1.6 billion for 2021
A laboratory manufacturing Pfizer’s Paxlovid in Freiburg, Germany. Fosun Pharma is also eligible to produce and supply the raw ingredients for the drug, which is called nirmatrelvir. Photo: AFP
